They could both outperform the market over the medium term, but one appears to have a clear edge.

Ohio University Distinguished Professor Alexander Govorov of the Department of Physics and Astronomy and the Nanoscale and ...

The drugmaker should significantly mitigate its most important risk as it develops new products.

Report Benchmarks Ownership Splits, Governance Terms, and Investment Structures Across the Top 25 Most Active Dealmakers Since 2016Dublin, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The "Joint Venture Deals ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The ...

The healthcare sector (XLV) gained 4.91% in August, outperforming the broader S&P 500 (SPY), which advanced 2.68% during the ...

December 2025 marked an exceptionally active period for life sciences regulation in the European Union (EU). Within the space of a few days, EU institutions have reached political agreement on the ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

How data-driven decision-making and integrated R&D systems can help India’s pharmaceutical and biotechnology sectors improve ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher ...